Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
NTRK3
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "NTRK3" in MCE Product Catalog:
2
2 Cited Publications
Synonyms: DS-6051b; AB-106; IBI-344
Target:
Domaines de recherche:
Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
Cat. No.: HY-RS09634
Target:
Domaines de recherche:
NTRK3 Human Pre-designed siRNA Set A contains three designed siRNAs for NTRK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-W070306
CAS No.: 1207836-10-9
Cat. No.: HY-RS09635
Target:
Domaines de recherche:
Ntrk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS09636
Target:
Domaines de recherche:
Ntrk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-131003A
CAS No.: 1505514-27-1
Synonyms: DS-6051b free base; AB-106 free base; IBI-344 free base
Target:
Domaines de recherche:
Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
Cat. No.: HY-101977A
CAS No.: 2097002-59-8
Synonyms: (R,S)-LOXO-195
Target:
Domaines de recherche:
(R,S)-Selitrectinib ((R,S)-LOXO-195) (compound 17) is a Trk inhibitor with activity against cancers harboring Trk inhibitor-resistant point mutations in NTRK1, NTRK2, or NTRK3 genes. (R,S)-Selitrectinib can be used for the research of trk inhibitor-resistant cancer .
Cat. No.: HY-P992308
Target:
Domaines de recherche:
Cat. No.: HY-P704944
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TrkC; NT-3 Growth Factor Receptor; NTRK3; TRKC
Cat. No.: HY-115541
CAS No.: 1877286-69-5
Domaines de recherche:
BRD4-IN-41 is a BRD4 inhibitor with an IC50 of 34 nM. BRD4-IN-41 also inhibits JAK2, FLT3, RET, ROS1, NTRK3, PDGFRb, and FGFR1 kinases with IC50 values ranging from 0.9 nM to 43 nM. BRD4-IN-41 inhibits acetyl-lysine binding site of BRD4, downregulates c-MYC, reduces phosphorylated STAT3 levels, induces G1 cell cycle arrest and apoptosis, thereby inhibiting cancer cells growth. BRD4-IN-41 can be used for the research of cancer, such as multiple myeloma and acute myeloid leukemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
